Benzomorphan Compounds for Opioid-Induced Constipation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Opioid analgesics often cause constipation due to their action on mu opioid receptors in the bowel, leading to inhibition of gastrointestinal motility, and existing solutions do not effectively address this side effect without compromising analgesic efficacy.
Innovation Solution
Development of novel benzomorphan compounds with dual activity as mu opioid antagonists and kappa opioid agonists, which are selectively restricted to the gastrointestinal tract, reducing constipation while maintaining analgesic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mu opioid agonists are administered to treat pain, then analgesic effect is improved, but constipation occurs due to inhibition of gastrointestinal motility
Solution Approach 1:
The invention segments the opioid receptor system into two distinct targets: mu receptors for analgesia and kappa receptors for gastrointestinal motility. By developing compounds that selectively target these separate receptor types, the patent divides the therapeutic function from the side effect mechanism, allowing independent optimization of each aspect.
Solution Approach 2:
The invention introduces kappa opioid receptors as intermediary targets to mediate gastrointestinal motility effects. Instead of directly blocking mu receptors in the gut (which would compromise analgesia), the patent uses kappa receptor activation as an intermediary mechanism to stimulate motility, thereby counteracting constipation while preserving pain relief.
2Ease of operation
If mu opioid receptor antagonists are co-administered to prevent constipation, then gastrointestinal motility is improved, but analgesic efficacy is reduced
Solution Approach 1:
The invention applies local quality by creating compounds with different selectivity profiles for different tissue locations. The dual-acting compounds exhibit kappa receptor selectivity in gastrointestinal tissue (promoting motility) while maintaining appropriate mu receptor activity in central pain pathways, thereby achieving location-specific therapeutic effects.
Solution Approach 2:
The invention changes the pharmacological parameters of opioid compounds by developing dual-acting molecules that simultaneously possess kappa agonist and mu antagonist properties. This parameter change allows the compounds to exert opposite effects on different receptor types, stimulating gastrointestinal motility through kappa activation while blocking constipating effects via mu antagonism.
3Object-generated harmful factors
If existing opioid combinations are used to address constipation, then device complexity is increased, but the side effect is not effectively eliminated
Solution Approach 1:
The invention merges multiple pharmacological functions into a single compound class. By combining mu antagonist and kappa agonist activities in one molecule, the patent eliminates the need for separate co-administered drugs, thereby reducing treatment regimen complexity while effectively addressing constipation.
Solution Approach 2:
The invention creates universal compounds that perform multiple functions simultaneously: providing analgesia through mu receptor modulation, stimulating gastrointestinal motility through kappa receptor activation, and preventing constipation. This multi-functionality eliminates the need for multiple separate medications and simplifies the overall treatment approach.
Data Source
AI summary
The invention relates to Benzomorphan Compounds of Formula (I): wherein X, R1, R2, R3, R4, and R5 are as defined herein. These compounds are useful for treating constipation preferably constipation caused by mu-opioid agonist therapy.